Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know

Group 1 - Shares of Syndax Pharmaceuticals (SNDX) have increased by 2.2% over the past four weeks, closing at $9.57, with a mean price target of $32.33 indicating a potential upside of 237.8% [1] - The mean estimate consists of 12 short-term price targets with a standard deviation of $10.46, where the lowest estimate of $17.00 suggests a 77.6% increase, and the highest estimate of $45.00 indicates a potential surge of 370.2% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 0.5% over the past month [11][12] Group 2 - SNDX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While consensus price targets may not be reliable indicators of actual stock gains, they can provide a directional guide for price movement [14]